Results 21 to 30 of about 2,404 (154)

Impact of Seasonal Nirsevimab Administration in Infants Born During the RSV Circulation Period on RSV-Related Hospitalizations: A Population-Based Study from Emilia-Romagna, Northern Italy

Vaccines
Background: Respiratory syncytial virus (RSV) is a leading cause of hospitalization in early infancy, with the greatest burden occurring in the first months of life. Following the COVID-19 pandemic, many countries experienced intensified RSV circulation.
Susanna Esposito, Matteo Puntoni, Giuseppe Maglietta, Alessandro De Fanti, Chiara Ghizzi, Giacomo Biasucci, Federico Marchetti, Melodie Olivia Aricò, Gianluca Vergine, Marcello Stella, Battista Guidi, Agnese Suppiej, Francesca Alberghi, Emanuele Filice, Maria Elena Capra, Enrico Valletta, Andrea Miceli, Cristina Malaventura, Beatrice Rita Campana, Valentina Fainardi, Caterina Caminiti   +20 more
doaj   +2 more sources

Nirsevimab Prophylaxis for Reduction of Respiratory Syncytial Virus Complications in Hospitalised Infants: The Multi-Centre Study During the 2023–2024 Season in Andalusia, Spain (NIRSEGRAND) [PDF]

Vaccines
Background: Nirsevimab was indicated in a population level for all infants < 6 months during the 2023–2024 season in Andalusia (southern Spain). Our aim was to analyse the effect of nirsevimab in the reduction in complications in infants hospitalised for
David Moreno-Pérez, Aleksandra Korobova, Francisco de Borja Croche-Santander, Ana Cordón-Martínez, Olga Díaz-Morales, Leticia Martínez-Campos, Elena Pérez-González, María del Carmen Martínez-Padilla, Juan Luis Santos-Pérez, Jaime Brioso-Galiana, María Isabel Sánchez-Códez, Jorge Del Diego-Salas, Mario Rivera-Izquierdo, Nicola Lorusso   +13 more
doaj   +2 more sources

Acceptance of Nirsevimab for the Prevention of Respiratory Syncytial Virus Infection in Neonates: A Cross-Sectional Survey in Emilia-Romagna, Italy

Vaccines
Background: Respiratory syncytial virus (RSV) bronchiolitis remains a leading cause of hospitalization in infants, particularly those with risk factors such as prematurity or chronic diseases.
Susanna Esposito, Valentina Fainardi, Maria Elena Capra, Melodie Aricò, Angela Lanzoni, Beatrice Rita Campana, Marta Niceforo, Cosimo Neglia, Enrico Valletta, Giacomo Biasucci, Serafina Perrone   +10 more
doaj   +2 more sources

Acceptance and impact of Nirsevimab and the RSVpreF vaccine following implementation in Austria [PDF]

Frontiers in Public Health
BackgroundSince summer 2024, passive immunization with nirsevimab (Beyfortus®) has been recommended for all infants in Austria to prevent severe respiratory syncytial virus (RSV) infection.
Michaela Höck, Wegene Borena, Jürgen Brunner, Karina Wechselberger, Johanna Scheiring, Elisabeth Ralser, Ulrike Pupp Peglow, Peter Wöckinger, Elisabeth D’Costa, Verena Kaiser, Klaus Kapelari, Gisa Gerold, Thomas Müller, Ursula Kiechl-Kohlendorfer, Elke Griesmaier   +14 more
doaj   +2 more sources

A single-center observational study of nirsevimab for prevention of RSV infection in preterm infants [PDF]

Frontiers in Pediatrics
ObjectiveThis study aims to evaluate the clinical efficacy of nirsevimab in preventing respiratory syncytial virus (RSV) infection in preterm infants, highlighting its potential to improve neonatal respiratory health.MethodsWe conducted a retrospective ...
Rina Su, Rigonggaowa A, Fang Yao, Yanbin An, Cheng Cai, Lei Yun   +5 more
doaj   +2 more sources

Potential Effects on Elderly People From Nirsevimab Use in Infants

Open Respiratory Archives
Nirsevimab therapy has the potential to revolutionize infant respiratory syncytial virus (RSV) prophylaxis. But other populations suffering RSV, such the elderly or those over 60, may also be protected by using this novel antibody in the infant group. It
Iván Sanz-Muñoz, Javier Castrodeza-Sanz, José M. Eiros   +2 more
doaj   +3 more sources

Efficacy and safety of monoclonal antibodies against respiratory syncytial virus disease in premature infants: a systematic review and network meta-analysis [PDF]

Frontiers in Pediatrics
ObjectiveRespiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infection (LRTI) in infants and young children, which may progress to bronchiolitis, pneumonia, and other severe respiratory complications.
Shunli Liu, Shunli Liu, Yan Wang, Yan Wang, Yang Cao, Yang Cao, Huiling Song, Huiling Song, Zhiqing Tian, Zhiqing Tian, Xue Li, Xue Li, Lan Huang, Lan Huang   +13 more
doaj   +2 more sources

RSV Monoclonal Antibody Implementation for At-Risk Infants: Victoria, Australia's 2024 Experience. [PDF]

Health Sci Rep
ABSTRACT Background New respiratory syncytial virus (RSV) preventative programs are launching globally. Our Australian jurisdiction implemented RSV monoclonal antibody provision via pediatric and perinatal hospitals for highest risk neonates and infants.
Tuckerman J, Cheng DR, Hunter G, Elia S, Hearn T, Verma D, Jacobs S, Carr J, Crawford NW.   +8 more
europepmc   +2 more sources

The New Era of Respiratory Syncytial Virus Protection for Infants: A Mini Review of Current Tools for Immunoprophylaxis. [PDF]

Acta Paediatr
ABSTRACT Aim This mini review describes the history of infant respiratory syncytial virus (RSV) immunoprophylaxis and the latest advances in this area. It also reviews the efficacy, safety and impact of the recently introduced prophylactic strategies. Method This narrative review is based on a targeted review of published literature, with emphasis on ...
Heinonen S, Vartiainen P.
europepmc   +2 more sources

Long-acting monoclonal antibodies and the evolving landscape of infant respiratory syncytial virus prevention. [PDF]

Pediatr Investig
Pediatric Investigation, Volume 10, Issue 4, Page 293-299, August 2026.
Wang R, Abu-Raya B, Obeid H, Xie Z.
europepmc   +2 more sources